Extramedullary multiple myeloma (EMM) is an aggressive subentity of multiple myeloma,
characterized by the ability of a subclone to thrive and grow independent of the bone …

This manuscript represents a review of lymphoblastic leukemia/lymphoma (acute
lymphoblastic leukemia/lymphoblastic lymphoma), acute leukemias of ambiguous lineage …

Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after
progress in the last decades. PCL deserves a prompt identification to start the most effective …

The monoclonal gammopathies are a group of disorders associated with monoclonal
proliferation of plasma cells. The characterization of specific entities is an area of difficulty in …

This is the third volume in the new World Health Organization series on histological and
genetic typing of tumours. Tumours of the haematopoietic and lymphoid tissues are covered …

Plasma cell leukemia (PCL) is a rare and aggressive variant of myeloma characterized by
the presence of circulating plasma cells. It is classified as either primary PCL occurring at …

1Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation
Trust, Bristol, 2Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds …

Plasma cell leukemia (PCL) is an aggressive and rare hematological malignancy that
originates either as primary disease (pPCL) or as a secondary leukemic transformation …

Life expectancy in patients with multiple myeloma is increasing because of the availability of
an increasing number of novel agents with various mechanisms of action against the …

Plasmablastic lymphoma was initially described as a variant of diffuse large B-cell
lymphoma (DLBCL) involving the oral cavity of HIV+ patients and characterized by …